JP2017522043A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522043A5
JP2017522043A5 JP2017510285A JP2017510285A JP2017522043A5 JP 2017522043 A5 JP2017522043 A5 JP 2017522043A5 JP 2017510285 A JP2017510285 A JP 2017510285A JP 2017510285 A JP2017510285 A JP 2017510285A JP 2017522043 A5 JP2017522043 A5 JP 2017522043A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017510285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522043A (ja
JP6449441B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2015/004424 external-priority patent/WO2015167293A1/en
Publication of JP2017522043A publication Critical patent/JP2017522043A/ja
Publication of JP2017522043A5 publication Critical patent/JP2017522043A5/ja
Application granted granted Critical
Publication of JP6449441B2 publication Critical patent/JP6449441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017510285A 2014-04-30 2015-04-30 FcRn特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物 Active JP6449441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
US61/986,742 2014-04-30
PCT/KR2015/004424 WO2015167293A1 (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (3)

Publication Number Publication Date
JP2017522043A JP2017522043A (ja) 2017-08-10
JP2017522043A5 true JP2017522043A5 (enExample) 2018-03-22
JP6449441B2 JP6449441B2 (ja) 2019-01-09

Family

ID=54358928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017510285A Active JP6449441B2 (ja) 2014-04-30 2015-04-30 FcRn特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物

Country Status (21)

Country Link
US (6) US10544226B2 (enExample)
EP (2) EP4241852A3 (enExample)
JP (1) JP6449441B2 (enExample)
KR (2) KR101954906B1 (enExample)
CN (2) CN106459215B (enExample)
AU (2) AU2015253915B2 (enExample)
CA (2) CA2945086C (enExample)
DK (1) DK3137504T5 (enExample)
EA (1) EA038470B1 (enExample)
ES (1) ES2952583T3 (enExample)
FI (1) FI3137504T3 (enExample)
HU (1) HUE062403T2 (enExample)
IL (2) IL248159B (enExample)
MX (2) MX382284B (enExample)
NZ (2) NZ726089A (enExample)
PL (1) PL3137504T3 (enExample)
PT (1) PT3137504T (enExample)
RS (1) RS64542B1 (enExample)
SA (1) SA516380194B1 (enExample)
SG (1) SG11201608208VA (enExample)
WO (1) WO2015167293A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
US10822417B2 (en) * 2016-04-25 2020-11-03 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
DK3491025T3 (da) * 2016-07-29 2024-01-15 Momenta Pharmaceuticals Inc Fcrn-antistoffer og anvendelsesmetoder heraf
AU2017394032B8 (en) 2017-01-21 2020-10-22 Guangzhou Hanfang Pharmaceutical Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EP3638305A1 (en) * 2017-06-15 2020-04-22 UCB Biopharma SRL Method for the treatment of immune thrombocytopenia
AU2018386193B2 (en) 2017-12-13 2025-04-24 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
WO2020097099A1 (en) * 2018-11-06 2020-05-14 Immunovant Sciences Gmbh Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
MX2022005862A (es) 2019-11-19 2022-06-23 Immunovant Sciences Gmbh Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn.
TWI869542B (zh) * 2020-02-10 2025-01-11 大陸商北京拓界生物醫藥科技有限公司 抗FcRn抗體、其抗原結合片段及其醫藥用途
JP2023532326A (ja) * 2020-06-29 2023-07-27 ハナル バイオファーマ カンパニーリミテッド 抗fcrn抗体のための製剤
CN116490208A (zh) * 2020-08-06 2023-07-25 史坦利科西斯治疗有限责任公司 Il-8抗体及其使用方法
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
WO2023016538A1 (en) * 2021-08-13 2023-02-16 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
US20250026814A1 (en) * 2021-11-16 2025-01-23 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
WO2023235679A1 (en) 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
CN119013043A (zh) * 2022-05-30 2024-11-22 韩兀生物制药股份有限公司 具有改善的稳定性的抗FcRn抗体或其抗原结合片段
AU2023313033A1 (en) * 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
EP4584295A1 (en) 2022-09-06 2025-07-16 Immunovant Sciences GmbH Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
IL319310A (en) 2022-09-06 2025-04-01 Immunovant Sciences Gmbh Methods for treating Graves' disease using anti-FCRN antibodies
KR20250156749A (ko) 2023-03-08 2025-11-03 이뮤노반트 사이언시스 게엠베하 폴리소르베이트 부형제를 포함하는 고농도 단백질 제제 및 이의 제조 방법
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025017368A1 (en) 2023-07-16 2025-01-23 argenx BV Methods of treating chronic inflammatory demyelinating polyneuropathy
WO2025093717A1 (en) * 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588A (zh) * 2024-10-17 2025-02-21 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2007501847A (ja) 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己/同種免疫状態の治療用抗FcRn抗体
US20100266530A1 (en) * 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
EP3382022A1 (en) 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
SG10201804513WA (en) * 2008-04-25 2018-07-30 Dyax Corp Antibodies Against Fcrn And Use Thereof
CN105622754B (zh) 2011-06-02 2019-12-27 戴埃克斯有限公司 Fc受体结合蛋白
KR20130071961A (ko) 2011-12-21 2013-07-01 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Similar Documents

Publication Publication Date Title
JP2017522043A5 (enExample)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
JP2013538057A5 (enExample)
FI3137504T3 (fi) Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
JP2018521638A5 (enExample)
JP2020525032A5 (enExample)
JP2018512138A5 (enExample)
JP2017522903A5 (enExample)
JP2018502561A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2017113028A5 (enExample)
JP2018537421A5 (enExample)
JP2016507555A5 (enExample)
JP2016511277A5 (enExample)
JP2014511179A5 (enExample)
JP2014524733A5 (enExample)
JP2019536806A5 (enExample)
JP2011514150A5 (enExample)
JP2018502060A5 (enExample)
JP2018535650A5 (enExample)
JP2017531427A5 (enExample)
JP2015517470A5 (enExample)
JP2012501670A5 (enExample)
JP2014500009A5 (enExample)
JP2018527919A5 (enExample)